New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
11:00 EDTOREX, MONT, FIVE, CIEN, ULTA, PAY, EBIX, NAV, HSHOptions with decreasing implied volatility
Options with decreasing implied volatility: OREX IDIX MONT FIVE CIEN ULTA PAY EBIX NAV HSH
News For OREX;MONT;FIVE;CIEN;ULTA;PAY;EBIX;NAV;HSH From The Last 14 Days
Check below for free stories on OREX;MONT;FIVE;CIEN;ULTA;PAY;EBIX;NAV;HSH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 4, 2014
07:34 EDTPAYVeriFone reports Q3 EPS 40c, consensus 35c
Subscribe for More Information
07:20 EDTNAVAugsut truck orders well ahead of expectations, says Jefferies
Subscribe for More Information
07:02 EDTCIENCiena sees Q4 revenue $570M-$610M, consensus $628.88M
Subscribe for More Information
07:01 EDTCIENCiena reports Q3 adjusted EPS 32c, consensus 29c
Subscribe for More Information
06:56 EDTNAVNavistar head says largest divestitures in past, Reuters says
Subscribe for More Information
05:24 EDTNAVAugust Class 8 truck orders below expectations, says Wells Fargo
Wells Fargo notes that ACT Research reported August Class 5-8 truck orders were up 14% year-over-year but declined 6% from July. Class 8 net orders were 25,400, up 30% year-over-year and down 16% sequentially from July, below Wells' expectation of 27,000-30,000. The firm says Class 8 orders remained strong, however. Wells believes the modest Class 8 truck backlog decline may be a short-term neutral to negative for truck-related stocks, such as Cummins (CMI), Navistar (NAV) and PACCAR (PCAR).
September 3, 2014
15:29 EDTCIEN, PAYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Joy Global (JOY), consensus 84c; VeriFone Systems (PAY), consensus 35c; Ciena (CIEN), consensus 29c; Mattress Firm (MFRM), consensus 60c; Methode Electronics (MEI), consensus 40c; UTi Worldwide (UTIW), consensus 1c.
09:20 EDTNAVPower Solutions deal a major win, says Roth Capital
After Navistar (NAV) announced plans to use Power Solutions' (PSIX) 8.8L propane engine in school buses, Roth Capital thinks the deal provides validation for Power Solutions' engines. The firm expects the stock to rise in the near-term and reiterates a $90 price target and Buy rating on the stock.
09:15 EDTNAVOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTPAYVeriFone Q3 results could bring another guidance raise, says Jefferies
Jefferies does not think expectations are too high into VeriFone's Q3 results tomorrow. The firm believes another FY14 guidance hike is possible, and that a beat and raise quarter would be positive for shares. Jefferies says the upside potential in Q3 is unlikely to be as big as Q2. It keeps a Buy rating on VeriFone with a $42 price target.
07:24 EDTNAVNavistar expects to finish FY14 with $300M in structural cost savings
Subscribe for More Information
07:23 EDTNAVNavistar: Q3 results reflect increased production, cost reductions
Subscribe for More Information
07:22 EDTNAVNavistar reports Q3 EPS (2c), consensus (67c)
Subscribe for More Information
September 2, 2014
15:37 EDTNAVNavistar September weekly volatility elevated into Q3 and outlook
Subscribe for More Information
15:32 EDTNAVNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Toll Brothers (TOL), consensus 45c; Navistar (NAV), consensus (66c); G-III Apparel (GIII), consensus 16c; Vince Holding (VNCE), consensus 24c; Dorian LPG (LPG), consensus 1c.
08:18 EDTOREXOrexigen receives new US patent related to NB32 intellectual property
Orexigen announced that the U.S. Patent and Trademark Office has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone and bupropion. The patent expires in 2024. If NB32 is approved for use in the United States, Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration. A counterpart application to this patent has issued in Europe and other international jurisdictions.
07:35 EDTCIENCiena recent pullback leads to better set-up for shares, says UBS
UBS believes the recent pullback in Ciena has led to a better set-up for the shares as expectations have been reduced. The firm sees limited downside risk, although some caution is warranted given concerns over softer Tier-1 capital expenditures. UBS keeps its Buy rating and $27 price target on Ciena.
07:33 EDTEBIXEbix purchases new buildings in India
Ebix announced that it has completed the purchase of two new buildings in Noida, India, in the Export Processing Zone of the Govt. of India. The company paid for the purchase using its own cash reserves in June. The company also announced that it has received a 100 percent tax-exempt status for these new buildings, until 2019, under the Software Export Zone, or SEZ, Act of the Govt. of India, after which the company is entitled to a 50% tax-free status in India until 2024. With this new purchase, the company now has a total of 10 offices in India spread across Noida, Chennai, Coimbatore, Nagpur, Hyderabad and Bangalore. Ebix presently employs in excess of 1,200 employees in India. These buildings will facilitate the Company's near- and long-term growth and acquisition plans and the associated need for offshore development and BPO resources.
07:22 EDTULTAUlta Salon remains a quality growth idea, says RW Baird
Subscribe for More Information
07:14 EDTCIENCiena September volatility elevated into Q3 and guidance
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use